IP Library Granted Patent US 7,285,699
Granted Patent B2
US 7,285,699 · App. 10/434,668 · Granted Oct 23, 2007

Ends-out gene targeting method

Assignee: Stowers Institute for Medical Research
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,285,699
App. No.
10/434,668
Granted
Oct 23, 2007
Kind
B2
Abstract

A gene targeting method for use in a host organism whereby the host organism is transfected with an ends-out donor construct. Further transfecting the host organism with two transgenes expressing endonuclease and recombinase enzymes. The endonuclease and recombinase enzymes are used so that homologous recombination occurs between the DNA segment of the donor construct and a selected gene of the host organism, thus forming a host with containing the recombinogenic donor. The progeny of the host organism, which include the recombinogenic donor are then selected.

Claims (19)

1. A method of gene targeting in Drosophila comprising:

(a) selecting a Drosophila target gene;

(b) providing a donor construct comprising a transposon and a DNA segment homologous to the target gene comprising a marker sequence, wherein the DNA segment is flanked at both ends by a rare-cutting endonuclease recognition site and additionally flanked by a recombinase recognition site;

(c) introducing the donor construct to a female Drosophila to obtain a transgenic female Drosophila whose genome comprises the transposon and the DNA segment flanked by said rare-cutting endonuclease recognition sites and said recombinase recognition sites;

(d) providing a construct comprising a DNA sequence encoding a rare-cutting endonuclease and a DNA sequence encoding a recombinase, wherein each DNA sequence is operably linked to an inducible promoter;

(e) introducing the construct of step (d) to a male Drosophila to obtain a transgenic male Drosophila whose genome comprises a DNA sequence encoding the rare-cutting endonuclease and a DNA sequence encoding the recombinase, wherein each DNA sequence is operably linked to an inducible promoter;

(f) crossing the male transgenic Drosophila and the female transgenic Drosophila to produce progeny whose genome comprises the transposon and the DNA segment flanked by the rare-cutting endonuclease recognition sites and recombinase recognition sites, and whose genome also comprises a DNA sequence encoding the rare-cutting endonuclease and a DNA sequence encoding the recombinase, wherein each DNA sequence is operably linked to an inducible promoter;

(g) activating the inducible promoter in the progeny of step (f) to express the rare-cutting endonuclease and the recombinase such that recombination occurs between the target gene and the target construct; and

(h) selecting a transgenic progeny whose genome comprises the disrupted target gene.

2. The method of claim 1 , wherein the inducible promoter is a heat shock promoter.

3. The method of claim 2 , wherein the heat shock promoter is the heat shock 70 (hsp70) promoter.

4. The method of claim 1 , wherein the endonuclease is selected from the group consisting of I-SceI, I-Tli, I-CeuI, I-PpoI, I-CreI, and PI-PspI.

5. The method of claim 1 , wherein the recombinase and its specific recognition site, respectively, are selected from the group consisting of the Cre and lox recombination system and the FLP and FRT recombination system.

6. The method of claim 1 , wherein the donor construct comprises DNA encoding one or more selectable markers.

7. The method of claim 6 , wherein the selectable marker provides positive selection for cells expressing the marker.

8. The method of claim 6 , wherein the selectable marker provides negative selection against cells expressing the marker.

9. The method of claim 6 , wherein the selectable markers provide positive and negative selection of cells expressing the markers.

10. The method of claim 1 , wherein the donor construct comprises DNA encoding a screenable marker.

11. The method of claim 10 , wherein the screenable marker is selected from the group consisting of beta-glucuronidase, green fluorescent protein, and Lucifers.

Assignments (3)
MERGER Recorded Feb 2, 2009
From: STOWERS INSTITUTE FOR MEDICAL RESEARCH
To: STOWERS MEDICAL INSTITUTE INC.
Reel/Frame 022191/0775 →
CHANGE OF NAME Recorded Feb 2, 2009
From: STOWERS MEDICAL INSTITUTE INC.
To: STOWERS INSTITUTE FOR MEDICAL RESEARCH
Reel/Frame 022203/0046 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 28, 2006
From: GOLIC, KENT G.; GONG, WEL J.
To: STOWERS INSTITUTE FOR MEDICAL RESEARCH
Reel/Frame 017296/0724 →
Continuity (2)
Provisional Application 6041656100 · Oct 7, 2002
Related Publication 20040068761A1 · Apr 8, 2004